IAR038 / Innovent Biologics - LARVOL DELTA

Innovent to Present Preclinical Data of Multiple Novel Molecules at the 2024 AACR Annual Meeting (PRNewswire) - "IAR038 has minimal activity in the absence of CD3, even under stringent conditions, different from benchmark antibody in clinical development. It demonstrated moderate activity in vitro in a CD3-dependent and PSMA-dependent manner. Notably, IAR038 elicited superior tumor killing in vivo and combined effectively with anti-PD1 antibody....In addition, it had an improved half-life compared with the Benchmark antibody. These features may translate to a wider therapeutic window and improved safety for CRPC patients."

Preclinical • Castration-Resistant Prostate Cancer • Oncology